San Diego, CA, August, 3, 2022 (street insider) — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced it has entered into a broad strategic collaboration and license agreement with Roche, focused on developing allogeneic CAR-T therapies directed to hematologic malignancies. The global collaboration covers the research and development of multiple existing and novel “off-the-shelf” cell therapies against targets in ..read more

IDRx aims to develop precision cancer medicines with a priori engineered, selective combinations to stop key tumor escape mechanisms and prolong response to therapy Pipeline includes small molecule tyrosine kinase inhibitors, IDRX-42 and IDRX-73, designed to inhibit key genetic drivers and resistance mutations of gastrointestinal stromal tumor (GIST) Company is launching at clinical stage with first-in-human study of IDRX-42 initiated Financing led by Andreessen Horowitz (a16z) and Casdin Capital, with participation from Nextech Invest, Forge Life Science Partners and other undisclo ..read more

Financing from new and existing investors will support pipeline progression and expansion for age-related degenerative diseasess BEIJING, Aug. 2, 2022 (PRNewswire) — Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases, today announced the completion of a $200 million Series B financing. The round was led by Gaorong Capital and Yunfeng Capital, with participation from existing investors including Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners ..read more

LEIDEN, Netherlands, Aug. 1, 2022 (PRNewswire) — Vico Therapeutics B.V., a neurology-focused genetic medicine company, today announced the appointment of Micah Mackison as Chief Executive Officer. Mr. Mackison brings significant biotechnology and pharmaceutical leadership experience to Vico. He will lead the company as it advances its neurology programs into the clinic and expands its oligonucleotide-based RNA modulation platform. Micah Mackison, CEO, VICO Therapeutics B.V. (PRNewsfoto/Vico Therapeutics B.V.) “We are very excited to welcome Micah to the Vico team,” sai ..read more

Nijmegen, Netherlands and Newark, N.J., July 26, 2022 (PRNewswire) — Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel treatments designed to detoxify the cancer promoting cellular micro-environment, today announces its expansion, with the incorporation if a U.S. subsidiary, Pleco Therapeutics USA, Inc., alongside the appointment of Michael Stalhamer as its President and first employee. Mr Stalhamer also serves on the global leadership team as Vice President (VP) Product Development and Regulatory Affairs. Incorporated in Delaware ..read more

San Mateo, CA, July 20, 2022 (BUSINESS WIRE) — BigHat Biosciences, a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, today announced it has raised a $75 million Series B funding round, led by Section 32, with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, GRIDS Capital, among others. The investment brings BigHat’s total funding to date to $100 million. Prior investors Andreessen Horowitz, 8VC, and AME Cloud Ventures also contributed to this round, which will ..read more

Cambridge, MA., July 20, 2022 (BUSINESS WIRE) — CAMP4 Therapeutics, a biotechnology company harnessing the power of RNA to restore healthy protein expression, today announced the closing of a $100 million Series B round to advance the company’s lead regRNA programs and accelerate the expansion of the company’s regRNA Actuating Platform. Enavate Sciences, a portfolio company created by Patient Square Capital, led the round. Additional investors in the Series B financing include a large national managed care organization and the Gaingels, an LGBTQIA+/Allies investment syndicate supporting divers ..read more

Horsham, PA., July 19, 2022 (PRNewswire) — Conventus Flower Orthopedics, a privately held medical technology company that pioneered the Ready-for-Surgery single-use, sterile packaged foot and ankle solutions and launched the first-to-market flexible intramedullary distal fibula nail, today announced that Brad Niemann has been appointed as the Company’s Chief Executive Officer (CEO), effective immediately. “The Board of Directors and Deerfield Management are pleased to have an incredible leader like Brad join Conventus Flower Orthopedics,” said Rick Epstein, Chairman of the Board. “His proven l ..read more

Baltimore and Palo Alto, CA., July 18, 2022 (PRNewswire) — Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, today announced a Series B funding of $225 million. This round of financing was led by DFJ Growth with participation from Eli Lilly and Company, Point72, Brown Advisory, Point Field Partners, Initiate Ventures, Open Field Capital, PTX Capital, and all existing investors including Cowen Healthcare Investments, Foresite Capital, Menlo Ventures, OrbiMed, funds and accounts advised by ..read more

Radnor, PA., July 13, 2022 (PRNewswire) — NRx Pharmaceuticals, Inc. (Nasdaq: NRXP): (“NRx Pharmaceuticals”, or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Stephen Willard, as its Chief Executive Officer (“CEO”) and a member of the Company’s Board of Directors. The Company’s interim CEO, Robert Besthof, will continue to support the Company and return to his roles as Head of Operations and Chief Commercial Officer. “We are delighted to have attracted a candidate like Steve whose background and experience align with NRx Pharmaceuticals’ current n ..read more